Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2008 09:12 ET | Source: Eurand N.V.

Eurand Announces Positive Pharmacokinetic Study Results of Once-a-Day Ondansetron

MILAN, Italy and DAYTON, Ohio, Feb. 26, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products...
February 21, 2008 08:00 ET | Source: Eurand N.V.

Eurand Granted Priority Review for Zentase NDA

PHILADELPHIA, Feb. 21, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
February 13, 2008 09:00 ET | Source: Eurand N.V.

Eurand Expands Clinical Development and Medical Affairs Management Team

MILAN, Italy and PHILADELPHIA, Feb. 13, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products...
February 07, 2008 09:00 ET | Source: Eurand N.V.

Eurand to Present At Deutsche Bank 2008 Small and Mid Cap Growth Conference

AMSTERDAM, The Netherlands, Feb. 7, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on...
February 04, 2008 09:00 ET | Source: Eurand N.V.

Eurand Announces Fourth Quarter 2007 and Year-end Financial Results Conference Call

AMSTERDAM, Feb. 4, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary...
January 09, 2008 10:07 ET | Source: Eurand N.V.

Eurand Announces Chief Scientific Officer Resigns

AMSTERDAM, Jan. 9, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary...
December 20, 2007 08:30 ET | Source: Eurand N.V.

Eurand Completes New Drug Application for Zentase

PHILADELPHIA, Dec. 20, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
December 18, 2007 08:30 ET | Source: Eurand N.V.

Eurand Announces NDA Filing by GSK for Co-development Product

PHILADELPHIA, Dec. 18, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
December 03, 2007 08:30 ET | Source: Eurand N.V.

Eurand Acquires Specialty Cystic Fibrosis Company

PHILADELPHIA, Dec. 3, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) announced today that Eurand Pharmaceuticals, Inc. has acquired the SourceCF family of companies ("SourceCF") for $6.6 million...
November 27, 2007 08:40 ET | Source: Eurand N.V.

Eurand Completes Bioavailability Study of Zentase

PHILADELPHIA, Nov. 27, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) announced today the completion of a gastrointestinal (GI) bioavailability study on Zentase(tm) (EUR-1008), the Company's lead...